GlassScriptPhysician profile
Linet Kairu
NPI 1942731864
$545.53
in general payments reported to CMS, 2019-2025
14 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $183 · 2022: $28.78 · 2023: $32.50 · 2024: $72.27 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $308 · Education: $25.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $307.98 |
| Education | $25.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $98.03 | 2025 | Vafseo |
| Biodelivery Sciences International, INC. | $89.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.28 | 2021-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $71.91 | 2024-2025 | |
| Calliditas Therapeutics US INC. | $31.20 | 2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $30.07 | 2024 | Acthar |
| Opko Pharmaceuticals, LLC | $25.34 | 2024 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $24.91 | 2025 | Lokelma |
| Lilly USA, LLC | $19.36 | 2025 | Jardiance |
| Abbvie INC. | $17.44 | 2021 | |
| Amgen INC. | $17.16 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.51 | 2023 | Entyvio |
| Teva Pharmaceuticals USA, INC. | $14.61 | 2022 | |
| Allergan, INC. | $14.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linet Kairu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.